MedTrace Logo

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Conditions

  • Carcinoma, Non-small-Cell Lung

Interventions

DRUG

JNJ-86974680

JNJ-86974680 will be administered.

DRUG

Cetrelimab

Cetrelimab will be administered.

RADIATION

Radiation Therapy

Radiation therapy will be administered.

Sponsors & Collaborators

  • Johnson & Johnson Enterprise Innovation Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Enterprise Innovation, Inc Clinical Trial · Johnson & Johnson Enterprise Innovation Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2027-04-14
Completion
2029-06-07
FDA Drug
Yes

Countries

  • United States
  • Germany
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06116786 on ClinicalTrials.gov